Medtronic reports positive data from PulseSelect PFA System in treating atrial fibrillation at APHRS meeting

Medtronic plc, a global leader in healthcare technology, has announced clinical results showing high rates of durable lesion formation using the PulseSelect Pulsed Field Ablation (PFA) System for atrial fibrillation (AFib) treatment. Invasive remapping performed around two months post-ablation revealed 98% durable isolation in pulmonary veins (PVs) and 96% of patients had all veins isolated.

The findings, presented at the Asia Pacific Heart Rhythm Society (APHRS) meeting in Sydney, Australia, highlighted the effectiveness of the PFA system. The study involved 25 AFib patients (56% with paroxysmal AFib, 52% male, mean age 69), and remapping at 57 days post-ablation showed durable PV isolation in 98% of cases.

All procedures were done without fluoroscopy, and 100% of patients achieved acute PV isolation, with no complications observed during the 74-day follow-up. PulseSelect has seen global adoption, with over 10,000 cases performed, supported by regulatory approvals in regions such as China, Australia, and Japan.